Ozonated olive oil
Phase 3Biologic
Ozonated olive oil is one of 60 biologic programs targeting Bullous Pemphigoid. It is currently in Phase 3.
2
Indications
4
Total Trials
1
Active Trials
59
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
65 competitors in Chronic Periodontitis
#DrugCompanyPhaseTrials
1Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Minocin
TTriax
Approved
Crestor
AstraZenecaPhase 3
Propolis
IIndonesia University
Approved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Glucophage
EMD SeronoPhase 3
Fosamax
OOrganon and Co
Phase 3
IC-Green
CCHX Technologies Inc.
Phase 3
Altoprev
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Spirulina
TTanta University
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Periodontal Diseases1 trial
Bullous Pemphigoid1 trial
Ozonated Olive Oil in Treatment of Pemphigus Vulgaris and Bullous Pemphigoid
Unknown status·—·Phase 3·NCT05594472·30 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ozonated olive oil. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- SSuez Canal University